Shares of Genfit S.A. (NASDAQ:GNFT - Get Free Report) shot up 2% on Tuesday . The stock traded as high as $4.75 and last traded at $4.62. 11,051 shares traded hands during mid-day trading, a decline of 26% from the average session volume of 14,856 shares. The stock had previously closed at $4.53.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "buy" rating and set a $13.00 price objective on shares of Genfit in a research report on Friday, February 7th.
View Our Latest Stock Analysis on Genfit
Genfit Stock Performance
The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.74 and a current ratio of 3.74. The firm's 50 day moving average is $3.62 and its 200 day moving average is $3.96.
Institutional Trading of Genfit
A hedge fund recently bought a new stake in Genfit stock. Millennium Management LLC bought a new position in Genfit S.A. (NASDAQ:GNFT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned about 0.33% of Genfit at the end of the most recent quarter. Institutional investors own 2.24% of the company's stock.
Genfit Company Profile
(
Get Free Report)
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Featured Articles
Before you consider Genfit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genfit wasn't on the list.
While Genfit currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
